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ABSTRACT
Introduction Tobacco smoke exposure (TSE) has 
considerable adverse respiratory health impact among 
children. Smoke- free policies covering enclosed public 
places are known to reduce child TSE and benefit child 
health. An increasing number of jurisdictions are now 
expanding smoke- free policies to also cover outdoor areas 
and/or (semi)private spaces (indoor and/or outdoor). We 
aim to systematically review the evidence on the impact 
of these ‘novel smoke- free policies’ on children’s TSE and 
respiratory health.
Methods and analysis 13 electronic databases will 
be searched by two independent reviewers for eligible 
studies. We will consult experts from the field and hand- 
search references and citations to identify additional 
published and unpublished studies. Study designs 
recommended by the Cochrane Effective Practice and 
Organisation of Care (EPOC) group are eligible, without 
restrictions on the observational period, publication date 
or language. Our primary outcomes are: self- reported or 
parental- reported TSE in places covered by the policy; 
unplanned hospital attendance for wheezing/asthma and 
unplanned hospital attendance for respiratory infections. 
We will assess risk of bias of individual studies following 
the EPOC or Risk Of Bias In Non- randomised Studies of 
Interventions tool, as appropriate. We will conduct separate 
random effects meta- analyses for smoke- free policies 
covering (1) indoor private places, (2) indoor semiprivate 
places, (3) outdoor (semi)private places and (4) outdoor 
public places. We will assess whether the policies were 
associated with changes in TSE in other locations (eg, 
displacement). Subgroup analyses will be conducted based 
on country income classification (ie, high, middle or low 
income) and by socioeconomic status. Sensitivity analyses 
will be undertaken via broadening our study design 
eligibility criteria (ie, including non- EPOC designs) or via 
excluding studies with a high risk of bias. This review 
will inform policymakers regarding the implementation 
of extended smoke- free policies to safeguard children’s 
health.
Ethics and dissemination Ethical approval is not 
required. Findings will be disseminated to academics and 
the general public.
PROSPERO registration number CRD42020190563.
INTRODUCTION
Tobacco smoke exposure (TSE) is an 
important cause of adverse respiratory health 
outcomes in children worldwide. TSE includes 
both second- hand smoke (SHS) and third- 
hand smoke (THS) exposure. SHS refers to 
the inhalation of emitted smoke, while THS 
Strengths and limitations of this study
 ► This systematic review will be the first to compre-
hensively synthesise the evidence regarding the 
impact of ‘novel smoke- free policies’ (ie, those cov-
ering (1) indoor private places (2) indoor semiprivate 
places (3) outdoor (semi)private places and (4) out-
door public places) on tobacco smoke exposure and 
health outcomes among children.
 ► This protocol has been designed in line with the 
Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses for Protocols guidelines and 
guidelines of the Cochrane Effective Practice and 
Organisation of Care.
 ► A possible limitation is that included studies might 
be heterogeneous in the policy, study design and 
data collection methods, which might limit our abili-
ty to synthesise the results using meta- analysis.
 ► The value of this systematic review depends on the 
quality and availability of the evidence on the topic.
 ► This work will be instrumental in informing effec-
tive policy- making regarding implementing novel 
smoke- free policies to protect children from the ad-
verse effects of tobacco smoke.
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exposure refers to the uptake of tobacco smoke resid-
uals from polluted surfaces after someone has finished 
smoking. TSE is estimated to cause 166 000 child deaths 
annually associated with an increased risk of respiratory 
tract infections (RTIs), wheezing and asthma.1 2
Safeguarding of child health provides justification 
to advocate for strong tobacco control measures.3 
Previous systematic reviews found that smoke- free poli-
cies in enclosed public places are successful in reducing 
adverse child health outcomes. Meta- analyses showed 
that these policies were followed by a 9.8% (95% CI 3.0% 
to 16.6%) reduction in hospital attendance for asthma 
exacerbations, and an 18.5% (95% CI 4.2% to 32.8%) 
reduction in hospital attendance for lower RTIs.2 These 
health impacts of smoke- free policies are likely medi-
ated through a reduction in SHS and potentially also in 
THS.1 Indeed, individual studies have demonstrated that 
smoke- free policies covering enclosed public areas are 
successful in decreasing child TSE in public places and 
even in private places, such as cars or homes, most likely 
via changes in social norms.4–8 Although in low- income 
and middle- income countries high background air pollu-
tion, poor economic conditions and low awareness of 
tobacco- related harm might obscure the positive effects 
of smoke- free legislation, evidence suggests that smoke- 
free policies can have a similarly positive impact in these 
countries as in high- income countries.9–11
As a result, smoke- free legislation is increasingly 
recognised as an important policy tool to protect children 
from the adverse health effects of TSE (eg, incorporated 
in Sustainable Development Goals 3.2, 3.4, 3.9 and 3.A 
that aim to improve health and well- being).3 Recently, 
policies to provide additional protection of children to 
TSE beyond enclosed public places have been imple-
mented in a number of places, both at a national and 
a subnational level. These include expansion to cover 
outdoor areas frequented by children such as school 
grounds, playgrounds and parks.12 Also, some countries 
and subnational regions have now implemented policies 
prohibiting smoking in semiprivate spaces such as shared 
housing or private spaces such as cars.13 14
The positive effects of smoke- free policies covering 
enclosed public places on child health are now well estab-
lished.2 15 A systematic synthesis of the evidence on the 
effectiveness of smoke- free policies covering outdoor 
and/or (semi)private spaces to reduce children’s TSE 
and benefit their health is however currently lacking.2 15 It 
is important to note that effectiveness of smoke- free poli-
cies covering indoor public places cannot be easily extrap-
olated to those covering outdoor or private spaces, due to 
various reasons (eg, dilution of TSE in outdoor spaces, 
enforcement issues). Further, evidence from various 
countries indicates that smoke- free policies covering 
public enclosed places and workplaces are followed by 
reductions in TSE even in areas not covered by the policy 
through norm spreading. Whether novel smoke- free poli-
cies also have an impact on TSE in places not covered 
by the policy is unclear. Theoretically, there may be a 
reduction (via norm spreading) in such places but there 
may also be displacement of smoking to areas not covered 
by the policy.14 Finally, effectiveness of smoke- free policies 
is likely to vary according to local rates of smoking and 
children’s SHS exposure, and comprehensiveness of the 
policy as well as compliance and enforcement.16
With an increasing number of institutions and govern-
ments now implementing smoke- free policies covering 
areas other than enclosed public spaces, optimal under-
standing of the effectiveness of such policies in protecting 
children is essential. To establish this evidence base, we 
will undertake a comprehensive systematic review of 
available studies assessing the impact of policies covering 
outdoor areas or/and (semi)private places (whether 
indoor or outdoor) on children’s TSE and respiratory 
health. We believe this work will be instrumental in 
informing effective policy- making, both (inter)nationally 
and locally, to further protect children from the adverse 
effects of tobacco smoke.
METHODS
This protocol is reported according to the Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses 
for Protocols (PRISMA- P) guideline for systematic review 
and meta- analysis protocols.17
Patient and public involvement
Patients and the public were not involved in the design, 
development, conduct, reporting or dissemination of this 
study.
Eligibility criteria
We will include studies based on predefined criteria as 
summarised in table 1 and detailed in the text below.18
Population
Studies are eligible when they include children between 
0 and 16 years. Any study reporting (sub)populations 
in which at least 50% fits this age criterion will also 
be eligible. Some studies may have included specific 
subgroups, for example, children with asthma.19 We will 
include all studies that meet the inclusion criteria, irre-
spective of such additional restrictions in the populations.
Interventions
We will include studies that evaluated smoke- free policies 
that were introduced at any governmental level (eg, cities, 
municipalities, regions or countries) or any institutional 
level (eg, school, hospital). The included policies might 
concern the following areas: indoor private places (eg, 
cars), indoor semiprivate places (eg, multiunit housing), 
outdoor (semi)private places (eg, shared gardens) 
and outdoor public places (eg, parks, school grounds, 
beaches, hospital grounds). We will exclude studies that 
solely evaluated policies covering enclosed public places 
(ie, ‘traditional’ smoke- free polices).
Smoke- free policies can be a part of a complex reform 
package.20 For example, the above- described smoke- free 
 on N
ovem
ber 25, 2020 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-038234 on 19 O
ctober 2020. D
ow
nloaded from
 
3Radó MK, et al. BMJ Open 2020;10:e038234. doi:10.1136/bmjopen-2020-038234
Open access
policy might be introduced simultaneously with other 
tobacco control policies (eg, increased taxes on tobacco 
products). We will include all studies that estimate the 
effect of smoke- free policies covering (semi)private or/
and outdoor places irrespective of whether other poli-
cies were introduced at the same time. If the effect of the 
smoke- free policy covering (semi)private or/and outdoor 
places has been disentangled from other interventions, 
we will extract the effect estimates from the analyses that 
most closely reflects that of this smoke- free policy.
Comparison
We will include studies that estimate the counterfactual 
scenario (ie, no change in smoke- free policy implemented) 
Table 1 Inclusion criteria based on PICOS strategy
PICOS Inclusion criteria Exclusion criteria
Population 1. 0–16 years old
2. (Sub)populations in which at least 50% is under 17 
years of age
Adult population without a distinct child subgroup
Intervention Smoke- free policies instituted at any governmental or 
institutional level that restrict smoking in designated 
(semi)private places or/and any outdoor areas
Smoke- free policies covering only enclosed public 
places
Comparison 1. A comparison population living in a location where 
no intervention was introduced/changed in the 
observational period
2. A comparison time period in which no intervention 
was introduced/changed
Outcomes I. Child TSE:
Primary outcome:
1. TSE in places covered by the policy (as reported by 
child and/or parent/primary caregiver)
Secondary outcomes:
1. TSE in places of which only some were covered by 
the policy or in unspecified places (as reported by 
child/parent/primary caregiver)
2. TSE in places not covered by the policy (as reported 
by child/parent/primary caregiver)
3. Cotinine or other specific biomarkers of TSE 
quantified in body fluids, hair, nails or on the skin
4. TSE assessed by wearable devices
II. Child health outcomes:
Primary outcomes:
1. Unplanned hospital attendance for wheezing/
asthma
2. Unplanned hospital attendance for RTIs
Secondary outcomes:
1. General incidence of wheezing/asthma
2. General incidence of RTIs
3. OME
4. Chronic cough
5. FEV1, FVC, FEV1/FVC ratio
1. Child TSE outcomes that are not specific to tobacco 
smoke (eg, PM2.5 and CO)
2. Outcomes that do not necessarily imply a change 
in child TSE (eg, changes in tobacco smoke 
constituent level in a room)
3. Outcomes assessing smoking initiation/cessation or 
smoking behaviour (eg, among parents)
Study design Included in the main analyses:
1. Randomised trials
2. Non- randomised trials
3. Interrupted time series
4. Controlled before–after studies
Included in sensitivity analyses:
1. Prospective cohort studies
2. Retrospective cohort studies
3. Uncontrolled before–after studies
Lung function represents FEV1, FVC, FEV1/FVC ratio.
CO, carbon monoxide; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; OME, otitis media with effusion; PICOS, 
Population, Intervention, Comparison, Outcomes, and Study design; PM2.5, fine particulate matter; RTI, respiratory tract infection; TSE, 
tobacco smoke exposure.
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using any of the following comparators: (1) a comparison 
population where no change in the observed smoke- free 
policy occurred in the observational period or (2) a compar-
ison time period in which no change in the observed smoke- 
free policy occurred.
Outcomes
We will include studies assessing the impact of the policy on 
two types of outcomes: (1) indicators of TSE and (2) respi-
ratory health outcomes. We have specified a wide range of 
outcomes to obtain a comprehensive overview of the entirety 
of available evidence on the topic. We will in our interpreta-
tion focus primarily on a small set of primary outcomes next 
to a larger set of secondary outcomes. Any study that reported 
step changes (immediate change in incidence) and/or slope 
changes (gradual change in incidence over time) in one or 
more of these outcomes will be eligible.
Studies that report on the following TSE indicators will 
be included:
Primary outcome:
1. TSE in places covered by the policy (as reported by the 
child/parent/primary caregiver).
Secondary outcomes:
1. TSE in places of which only some were covered by the 
policy, or in unspecified places (as reported by the 
child and/or parent/primary caregiver).
2. TSE in places not covered by the policy (as reported by 
the child/parent/primary caregiver).
3. Cotinine or other specific biomarkers of TSE quanti-
fied in body fluids, hair, nails or on the skin.
4. TSE assessed by wearable devices.
Note that the primary TSE outcome of interest assesses 
exposure specifically in places covered by the policy. That 
is, we aim to assess whether the policy was successful in 
reducing child TSE in those places that it was intended to 
cover. In addition, unintended effects of smoke- free poli-
cies on TSE have been described, both positive (spillover; 
eg, via increased adoption of voluntary home smoking bans 
following the implementation of smoke- free policy) and 
negative (displacement; eg, via increased smoking at home 
following smoke- free vehicle regulation).14 In order to iden-
tify such effects, we will also identify studies that have assessed 
changes in TSE in places not covered by the policy.
Individual studies may report different estimates 
for TSE based on various definitions. We will prioritise 
child- reported TSE outcomes over parental or primary 
caregiver reported outcomes for studies reporting both. 
Furthermore, we will prioritise past- week TSE outcomes 
over longer or shorter recall periods. If past- week TSE is 
not available, longer recalls are prioritised over shorter 
recall periods.
The reduction in child TSE is anticipated to translate 
into child health benefits. Health outcomes are selected 
based on severity and responsiveness to changes in TSE 
within a reasonably short time frame (ie, within 1 year), 
these primarily being respiratory outcomes.2 15 Accord-
ingly, we will include studies that report the following 
outcomes:
Primary outcomes:
1. Unplanned hospital attendance for wheezing/asthma.
2. Unplanned hospital attendance for RTIs.
Secondary outcomes:
1. General incidence of wheezing/asthma.
2. General incidence of RTI.
3. Otitis media with effusion (OME).
4. Chronic cough.
5. Lung function (forced expiratory volume in one sec-
ond (FEV1), forced vital capacity (FVC), FEV1/FVC 
ratio).
Unplanned hospital attendance may include acute pres-
entations to the accident and emergency department as 
well as hospital admissions. For the secondary outcomes, 
respiratory diseases may be based on different case defini-
tions. For studies reporting estimates according to various 
definitions, we will prioritise according to the following 
hierarchy: (1) based on physician diagnosis, (2) based 
on medication use (not applicable for OME) and (3) 
self- reported.
We will not include perinatal outcomes in this review 
as many of the policies for which we anticipate to iden-
tify evidence are specifically aimed at protecting chil-
dren, not pregnant women (eg, smoke- free policies in 
playgrounds).
Study designs
We will follow the guidelines of the Cochrane Effective 
Practice and Organisation of Care (EPOC) group to select 
eligible study designs.21 EPOC established criteria for 
high- quality methodologies in research. These include: 
(1) randomised trials, (2) non- randomised trials, (3) 
interrupted time series and (4) controlled before–after 
studies. We will include studies that satisfy these criteria 
in our main analysis. Based on previous experiences, 
this restriction may sometimes lead to a lower number 
of studies being eligible. In order to properly assess the 
available evidence in such instances, we will conduct 
sensitivity analyses by relaxing the inclusion criteria.2 22 
For the sensitivity analyses, we will additionally include 
(1) prospective cohort studies, (2) retrospective cohort 
studies and (3) uncontrolled before–after studies.
Further restrictions
There will be no restriction on publication date, the time-
frame of the study or the length of follow- up after the 
introduction of the policy. All databases will be searched 
from their date of inception, and we will update the search 
to supplement our review just before publication. We 
will include every study that meets the above- mentioned 
criteria regardless of the language. Studies published in 
languages other than English will be translated. Google 
Translate will be used for this purpose, and we will consult 
with a translator if necessary.
Report type
Our systematic review will include published studies 
in scientific journals as well as in the ‘grey literature’ 
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(ie, documents that are circulated in non- commercial 
academic channels or/and not indexed by major data-
bases). Only full reports will be included in our review. 
Studies for which only an abstract was published will not 
be included since risk of bias for these studies cannot 
be adequately assessed. In these cases, however, we will 
contact the authors to ask if a full report is available.
Information sources
We will search for potential studies in the following electronic 
databases: (1)  Embase. com, (2) Medline Ovid, (3) Web of 
Science, (4) PsycINFO Ovid, (5) CINAHL EBSCOhost, (6) 
Google Scholar, (7) IndMED, (8) KoreaMed, (9) EconLit, 
(10) WHO Global Health Library (including African Index 
Medicus, Latin America and the Caribbean Literature on 
Health Sciences, Index Medicus for the Eastern Mediter-
ranean Region, Index Medicus for South- East Asia Region, 
Western Pacific Region Index Medicus, (11) WHO Library 
Database, (12) Scientific Electronic Library Online and (13) 
Paediatric Economic Database Evaluation.
Search strategy
First, we will search for potentially relevant studies based 
on a search strategy that is the combination of Medical 
Subject Headings (MeSH) terms and free text search. Our 
research team, including a librarian who is specialised in 
search strategy optimisation, has developed this search 
strategy. Search terms were tailored to each database. By 
means of an example, search terms used for  Embase. com 
database are available in online supplemental appendix. 
Search terms included four parts: (1) terms to identify 
smoke- free policies; (2) terms that identify children as the 
target population; (3) terms to identify asthma, wheezing, 
respiratory diseases, OME, chronic cough, lung function 
or TSE as outcome and (4) terms that exclude confer-
ence abstracts, letter to the editors, notes and editorials.
Second, we will search for additional studies by 
screening reference lists of included studies and their cita-
tions through Google Scholar. Moreover, we will contact 
with experts in the field to identify additional studies 
that may have been missed and any relevant ongoing or 
unpublished studies. Finally, we will update our search to 
add the most recent publications just before submitting 
the review for publication.
Study records
Data management
We will extract all records identified by the different sources 
into an EndNote Library, and use this software to automat-
ically deduplicate the collected records according to the 
method previously described.23 Subsequently, we will manu-
ally identify and remove any duplicates that remain. At this 
stage, duplicates will be identified based on overlaps in the 
authors’ names, the titles of the publication, the observed 
populations, the constructions of the treatment group and 
control groups, sample sizes and the reported outcomes. In 
our final report, we will note the number of duplicates in the 
PRISMA flow diagram.
Selection process
After the deduplication process, we will select eligible 
papers from the remaining unique records. At the first 
step, two independent researchers will screen titles and 
the abstracts for eligibility. We will then obtain the full- 
text reports of studies that may fit eligibility criteria based 
on this assessment. At the next step, two independent 
researchers will assess eligibility based on the full texts. 
Any discrepancies will be resolved after discussion with 
a third researcher. The involved researchers will not be 
blinded to information about the articles (eg, authors’ 
names and affiliations) at any stage.
Data collection process
Two researchers will independently extract data from 
the included studies to a customised data extraction 
form developed a priori that has been piloted using six 
eligible studies. After finishing the data extraction, they 
will confer their results with each other and create one 
final file. Again, any discrepancies will be resolved after 
discussion with a third researcher. We will contact authors 
for any relevant missing data.
In case overlapping populations are analysed in 
multiple studies, we will include according to the 
following hierarchy the study that (1) has the lowest risk 
of bias (see risk- of- bias assessment below), (2) evaluates 
the most comprehensive policy or (3) incorporates the 
largest sample size. In case one study reports multiple 
effect estimates for overlapping populations, we will select 
according to the following hierarchy the one derived 
from (1) the most adjusted model, (2) the longest obser-
vation period, (3) the most comprehensive policy or (4) 
the largest treatment group.
Data items
From eligible studies, we will extract the following items: 
(1) the first author’s name, (2) his or her affiliation, (3) 
publication year, (4) type of publication (journal, book, 
dissertation, etc), (5) access information (URL or doi), 
(6) study design, (7) observational period (the beginning 
and end dates), (8) exact places covered by the policy, 
(9) whether the policy covers outdoor or indoor places, 
(10) whether the policy covers public or (semi)private, 
places, (11) timing of policy, (12) institution/govern-
ment that initiated the policy, (13) country/location 
where the policy had been implemented, (14) compli-
ance with the policy, (15) enforcement of the policy, 
(16) eligibility criteria for inclusion, (17) description of 
control group(s), (18) population at risk, (19) number 
of participants/events, (20) control and treatment group 
size, (21) characteristics of the population and the treat-
ment groups (eg, age, gender and socioeconomic status), 
(22) data source(s) used for the study, (23) definition(s) 
of outcome measure(s), (24) controlled confounders (if 
applicable), (25) applied statistical techniques to draw 
inference, (26) number of clusters (if applicable), (27) 
cluster size (if applicable), (28) whether the results were 
adjusted for clustering (if clustered study), (29) whether 
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the intraclass correlation coefficient is reported and what 
it is (if clustered study), (30) the number of drop- outs/
missing values, (31) techniques for handling missing 
values, (32) preintervention population at risk(n)/
events(n)/rates (%) of outcome variable(s), (33) postin-
tervention population at risk(n)/events(n) rates (%) of 
outcome variable(s), (34) association between smoke- free 
policy and outcome(s) (coefficients, CIs and p values), 
(35) any unintended effects (eg, TSE displacement), (36) 
proportion of children exposed to TSE in the location 
covered by the smoke- free policy, before and after the 
implementation of the policy, (37) risk ratios (RRs) of 
respiratory disease for different levels of TSE according 
to specific locations covered by the smoke- free policy, 
(38) bias assessment (see section ‘Risk of bias assess-
ment’), (39) elements supporting causal inference (see 
section ‘Elements supporting causal inference’), (40) any 
conflict of interest reported by the authors and (41) the 
funding source(s).
Outcomes and prioritisation
As previously detailed, we will identify studies evaluating 
the effects of smoke- free policies on children’s (1) TSE 
and (2) health outcomes. See the description of outcomes 
and our prioritisation in the ‘Eligibly criteria’ section.
Risk of bias assessment
For each individual result, we will assess risk of bias using 
standardised assessment tools. For randomised trials, we 
will use the quality assessment tool for quantitative studies, 
developed by EPOC.24 For non- randomised studies, we 
will use the Risk Of Bias In Non- randomised Studies of 
Interventions (ROBINS- I) tool.25 The ROBINS- I tool 
evaluates biases in the following domains: (1) bias due 
to confounding (online supplemental appendix table 
1), (2) bias in selection of participants into the study, (3) 
bias in classification of interventions, (4) bias due to devi-
ations from intended interventions (see online supple-
mental appendix), (5) bias due to missing data, (6) bias 
in measurement of outcomes and (7) bias in selection 
of the reported result. For each domain, we will rate the 
risk of bias on a 4- point scale ranging from critical risk of 
bias to low risk of bias (ie, bias is comparable to a well- 
performed randomised trial). The ROBINS- I tool will be 
followed to give an overall estimate of the risk of bias. The 
risk- of- bias assessments will be conducted independently 
by two researchers and a third reviewer will be consulted 
to resolve disagreements.
Elements supporting causal inference
Based on information reported in the included studies, 
we will reflect on elements that may support causal infer-
ence and the robustness of the evidence using the UK 
Medical Research Council guidance on natural experi-
ments.26 First, we will report whether the effect estimates 
were robust when using alternative comparison groups 
(eg, the use of different populations living in distinct 
geographical areas as a comparison). Second, we will 
report whether a study estimated whether the smoke- free 
policy also had an ‘effect’ on neutral outcomes that were 
not expected to change as a consequence of the interven-
tion (eg, hospital admission for appendicitis). Finally, we 
will report from the included studies any additional infor-
mation from complementing research methodologies 
regarding possible underlying mechanisms supporting 
the quantitative study findings. These assessments will 
be based on the quantitative and qualitative informa-
tion presented in the individual study reports. We antici-
pate that this information cannot be uniformised across 
studies, and as such will be reported narratively.
Data synthesis
Synthetisation of data
Obtaining comparable data is essential to facilitate meta- 
analysis. Studies should be sufficiently similar in terms 
of their designs and the definitions of their measure-
ments. We will uniformise outcome assessments before 
conducting data analysis. First, if continuous outcomes 
appear on different scales across studies, we will use 
standardised mean differences. If continuous outcomes 
appear on the same scale, weighted mean differences 
will be used. Second, for dichotomous outcomes, we will 
extract relative risks. If only absolute risks are presented, 
then we will calculate relative risks. Third, we will express 
the effects on dichotomous outcomes usingRR. If RR was 
not reported, we will contact the authors to provide it to 
us. If the requested data were not be obtained, we will 
convert OR to RR using the following formula:
 
RR = OR(
1−PEER
)
+
(
PEER×OR
)
 
, where  refers to the patient- expected event rate in 
the control group.27 In case PEER is not available, we 
will approximate this measure using the overall event 
rate across the entire study population. We will use inci-
dence rate ratios instead of RR for outcomes that could 
occur repeatedly with the same individual (ie, hospital-
isation). To make different TSE measures comparable, 
we will convert them into a binary variable with a value 
of 1 if the child was exposed to (detectable amounts of) 
TSE and 0 if unexposed to (detectable amounts of) TSE. 
Finally, two researchers will check independently whether 
the definitions of intervention, population and outcomes 
are sufficiently comparable across the selected studies to 
allow meta- analysis.
The eligible studies are likely to be heterogeneous 
in various important characteristics that will be taken 
into account in the data synthesis. Therefore, we will 
apply random effects models (as opposed to fixed- effect 
models) for data analysis of two or more studies with 
similar policies and outcome measure. Furthermore, it 
might be needed to take into account the dependency 
of observations, for example, if multiple effect estimates 
for similar policies across various regions were provided 
within a single study. A three- level meta- analysis will be 
considered if multiple estimations are extracted from 
the same study. The decision to perform a two- level or 
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three- level meta- analysis will be based on the model 
performance using a one- sided log- likelihood- ratio 
test.28 29 We will separately pool step changes (immediate 
changes) and slope changes (gradual changes) for each 
outcome in different models. If unspecified, the result 
will be considered a step change. We will conduct sepa-
rate meta- analyses for various subtypes of smoke- free 
policies, according to the locations that they cover. Thus, 
we will separately pool studies for (1) smoke- free policies 
covering indoor private places (eg, cars), (2) smoke- free 
policies covering indoor semiprivate places (eg, multi-
unit housing), (3) smoke- free policies covering outdoor 
private or semiprivate spaces (eg, shared gardens) and (4) 
smoke- free policies covering outdoor public places (eg, 
parks, school grounds, beaches and hospital grounds). 
Finally, regarding TSE, we will pool separate models 
to assess unintended effects of the policy in places not 
covered by the policy.
The estimations of our meta- analysis will be displayed 
in forest plots. Heterogeneity will be quantified by the I² 
statistic for each pooled model.
We anticipate that most studies will have assessed the 
impact of novel smoke- free policies on TSE rather than 
on health outcomes. As the relationship between TSE 
and respiratory outcomes among children is well estab-
lished,30 31 we will use data from studies estimating the 
impact of novel smoke- free policies on child TSE to quan-
tify the potential impact of these changes on our primary 
health outcomes. Thus, we will perform a health impact 
assessment and quantify the proportion of children with 
respiratory disease that can be prevented by the change 
in TSE following smoke- free policies. First, we will extract 
the RR of respiratory disease for those children who were 
exposed to TSE versus those who were not either from the 
studies included in our systematic review or from previous 
meta- analyses that quantified this association.30 31 Prefer-
ably, this RR will be retrieved for the specific locations 
that are covered by the smoke- free policy and for distinct 
respiratory diseases. Second, based on the RRs and the 
difference in the proportion of children exposed to TSE 
before and after the policy implementation, we will calcu-
late two population attributable fractions (PAFs). One 
quantifies the proportion of each outcome that can be 
attributed to TSE before the smoke- free policy and the 
other after the policy’s implementation. The difference 
of these PAFs will give us the potential impact fraction 
capturing the change in the outcomes when the TSE 
level changes following a novel smoke- free policy’s 
implementation.
Sensitivity analyses
Three sets of sensitivity analyses will be conducted. First, 
excluding results with a higher risk of bias might lead 
to different estimations. Thus, we will conduct meta- 
regression analyses using the overall risk of bias based 
on the ROBINS- I assessment to test if effect sizes differ 
according to the overall risk of bias. Second, the ques-
tion may arise whether a less restrictive selection strategy 
regarding study design would lead to different results. 
We will check for the robustness of our results by addi-
tionally including studies applying not only methodolo-
gies considered as the state of the art in the Cochrane 
EPOC guidelines, but also study designs with a larger risk 
of bias.21 Third, we will test the sensitivity of our results to 
the selection of studies when overlapping populations are 
analysed in multiple studies.
Subgroup analyses
We will conduct subgroup analyses to evaluate whether 
smoke- free policies have differential effects among 
certain subgroups. To assess whether policies introduced 
in high- income countries have a different effect than 
policies introduced in low- income or middle- income 
countries, we will perform meta- regression based on the 
World Bank classification.32 Second, previous studies have 
shown that smoke- free policies have a different effect 
according to individuals’ SES.22 33–35 We will extract infor-
mation from subgroup analyses by SES indicators where 
possible and perform separate meta- analyses for high and 
low SES groups.
Meta-bias assessment
In each meta- analysis, we will assess the extent of publi-
cation bias via funnel plots when at least 10 studies are 
available. Furthermore, we will look for unpublished 
studies for which a protocol was registered, and we will 
contact the authors of these studies to obtain their results. 
Subsequently, we will compare the findings of these 
unpublished studies with those of the published reports. 
Finally, we will look for published reports that followed a 
registered protocol. We will compare these protocols with 
the final papers to check whether selective reporting was 
present at any stage.
Confidence in cumulative estimate
We will discuss the strength of the evidence on the 
association between implementation of smoke- free 
policies covering (semi)private or/and outdoor places 
and the TSE and child respiratory health outcomes 
based on the effect sizes, the variances of the estimated 
effects, the estimated level of heterogeneity between 
studies, sensitivity analyses, subgroup analyses, risk of 
bias, elements supporting causal inference and publi-
cation bias.
ETHICS AND DISSEMINATION
Ethical approval will not be required because we will 
only be using aggregate- level published data from 
previous studies. We expect to complete the study until 
September 2020, and before submitting for publica-
tion, we will update our search and include any addi-
tional eligible papers that may be identified. We will 
publish our results in a peer- reviewed international 
journal and report the research findings according to 
the PRISMA guideline.36 Finally, we will disseminate 
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our results to the public and policy- makers following 
the acceptance of our paper (eg, actively seek media 
attention and interaction with policy makers and 
other relevant stakeholders).
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